Introduction
Historical and forecast analysis of the entire generics industry from 2005 through to 2015. Strategic dynamics within the sector are broken down by company, geography, therapy area and formulation. See how Big Pharma companies' strategic shift away from blockbuster small molecule products will impact generics companies.
Features and benefits
The generics industry has developed significantly over the past decade and represents an integral element of the broader prescription pharmaceutical market. This role as the ‘commoditizer’ of the pharmaceutical industry will remain intact; however, the level of sales growth achieved by the generics industry in recent years will not be sustainable.
Sales growth will slow due to a fundamental change in the growth strategies implemented by branded players - Big Pharma in particular - which have become characterized by a smaller number of blockbuster launches and increased investment in biologics and vaccines.
Your key questions answered
Historical and forecast analysis of the entire generics industry from 2005 through to 2015. Strategic dynamics within the sector are broken down by company, geography, therapy area and formulation. See how Big Pharma companies' strategic shift away from blockbuster small molecule products will impact generics companies.
Features and benefits
- Analyze historical and forecast generics sales by geography, therapy area, formulation and company
- Analyze the relationship between the branded prescription pharmaceutical industry and the generics sector
The generics industry has developed significantly over the past decade and represents an integral element of the broader prescription pharmaceutical market. This role as the ‘commoditizer’ of the pharmaceutical industry will remain intact; however, the level of sales growth achieved by the generics industry in recent years will not be sustainable.
Sales growth will slow due to a fundamental change in the growth strategies implemented by branded players - Big Pharma in particular - which have become characterized by a smaller number of blockbuster launches and increased investment in biologics and vaccines.
Your key questions answered
- Assess the outlook for the generics industry through to 2015
- Evaluate the effects of the end of Big Pharma’s blockbuster era on the generics industry
Executive Summary
Key findings
Introduction to the global generics market
Big Pharma has learnt to take the generics industry seriously
Industry growth has become dependent on blockbuster expiries
Biosimilars the next phase of development for the generics industry?
Historical growth analysis 2005-09
US market central to industry growth
Generic players have ‘piggybacked’ blockbuster boom
Market growth forecast to slow over 2009-15
US market will act as primary growth resistor
Branded players have adapted – generic industry will be forced to follow
Fundamental shift in generic landscape over next decade
Biosimilars – the key growth opportunity for generics manufacturers?
US approval pathway delay highlights ‘bioequivalence’ issue
Biosimilars market could attract diverse competition
Erosion dynamics will be much different to typical generics market
ABOUT THIS SECTOR REPORT
PharmaVitae Explorer database
Chapter structure
Methodology
Market analysis
Company analysis
METHODOLOGY
Definitions
Forecasting methodology
Marketed products
New generic launches
Biosimilars
MARKET ANALYSIS
Key findings
Global generics market sales and growth rate analysis, 2005–15
Generic sales growth analysis, 2005-09
Generic sales growth analysis, 2009-15
Marketed and pipeline growth analysis, 2005-15
Geographic analysis
US market to deliver significant reduced sales growth
Non-US generic markets performance
Commoditization of generics market will fuel RoW/emerging market growth
Therapy area analysis
Central nervous system
Cardiovascular
Infectious diseases
Non-core generic market therapy areas
Formulation analysis
COMPANY ANALYSIS
Key findings
Leading generics companies
Teva
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Sandoz
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Mylan
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Apotex
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Hospira
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Ranbaxy
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Watson
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
APPENDIX
References
Abbreviations
Exchange rates
Key findings
Introduction to the global generics market
Big Pharma has learnt to take the generics industry seriously
Industry growth has become dependent on blockbuster expiries
Biosimilars the next phase of development for the generics industry?
Historical growth analysis 2005-09
US market central to industry growth
Generic players have ‘piggybacked’ blockbuster boom
Market growth forecast to slow over 2009-15
US market will act as primary growth resistor
Branded players have adapted – generic industry will be forced to follow
Fundamental shift in generic landscape over next decade
Biosimilars – the key growth opportunity for generics manufacturers?
US approval pathway delay highlights ‘bioequivalence’ issue
Biosimilars market could attract diverse competition
Erosion dynamics will be much different to typical generics market
ABOUT THIS SECTOR REPORT
PharmaVitae Explorer database
Chapter structure
Methodology
Market analysis
Company analysis
METHODOLOGY
Definitions
Forecasting methodology
Marketed products
New generic launches
Biosimilars
MARKET ANALYSIS
Key findings
Global generics market sales and growth rate analysis, 2005–15
Generic sales growth analysis, 2005-09
Generic sales growth analysis, 2009-15
Marketed and pipeline growth analysis, 2005-15
Geographic analysis
US market to deliver significant reduced sales growth
Non-US generic markets performance
Commoditization of generics market will fuel RoW/emerging market growth
Therapy area analysis
Central nervous system
Cardiovascular
Infectious diseases
Non-core generic market therapy areas
Formulation analysis
COMPANY ANALYSIS
Key findings
Leading generics companies
Teva
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Sandoz
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Mylan
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Apotex
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Hospira
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Ranbaxy
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
Watson
Sales analysis
Therapy area analysis
Formulation analysis
Geographic analysis
APPENDIX
References
Abbreviations
Exchange rates